Your browser doesn't support javascript.
loading
Latent process model of the 6-minute walk test in Duchenne muscular dystrophy : A Bayesian approach to quantifying rare disease progression.
Lennie, Janelle L; Mondick, John T; Gastonguay, Marc R.
Afiliação
  • Lennie JL; Metrum Research Group, Tariffville, CT, 06081, USA. janellelennie@gmail.com.
  • Mondick JT; University of Connecticut, Storrs, CT, 06268, USA. janellelennie@gmail.com.
  • Gastonguay MR; Metrum Research Group, Tariffville, CT, 06081, USA.
J Pharmacokinet Pharmacodyn ; 47(1): 91-104, 2020 02.
Article em En | MEDLINE | ID: mdl-31960231
Duchenne muscular dystrophy (DMD) is a rare X-linked genetic pediatric disease characterized by a lack of functional dystrophin production in the body, resulting in muscle deterioration. Lower body muscle weakness progresses to non-ambulation typically by early teenage years, followed by upper body muscle deterioration and ultimately death by the late twenties. The objective of this study was to enhance the quantitative understanding of DMD disease progression through nonlinear mixed effects modeling of the population mean and variability of the 6-min walk test (6MWT) clinical endpoint. An indirect response model with a latent process was fit to digitized literature data using full Bayesian estimation. The modeling data set consisted of 22 healthy controls and 218 DMD patients from one interventional and four observational trials. The model reasonably described the central tendency and population variability of the 6MWT in healthy subjects and DMD patients. An exploratory categorical covariate analysis indicated that there was no apparent effect of corticosteroid administration on DMD disease progression. The population predicted 6MWT began to rise at 1.32 years of age, plateauing at 654 meters (m) at 17.2 years of age for the healthy population. The DMD trajectory reached a maximum of 411 m at 8.90 years before declining and falling below 1 m at age 18.0. The model has potential to be used as a Bayesian estimation and posterior simulation tool to make informed model-based drug development decisions that incorporate prior knowledge with new data.
Assuntos
Palavras-chave

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Distrofia Muscular de Duchenne Tipo de estudo: Prognostic_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: J Pharmacokinet Pharmacodyn Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Distrofia Muscular de Duchenne Tipo de estudo: Prognostic_studies Limite: Adolescent / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: J Pharmacokinet Pharmacodyn Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos